DSpace Repository

Topiramate: A novel therapeutic candidate for diabetes and aggression? positron emission tomography (PET) findings

Show simple item record

dc.contributor.author Yulug, B.
dc.contributor.author Hanoglu, L.
dc.contributor.author Tavli, A.M.
dc.contributor.author Cakir, T.
dc.contributor.author Olmuscelik, O.
dc.contributor.author Pakoz, B.
dc.contributor.author Ünlü, Gülşen.
dc.date.accessioned 2019-08-16T13:07:22Z
dc.date.available 2019-08-16T13:07:22Z
dc.date.issued 2016
dc.identifier.issn 18715249 (ISSN)
dc.identifier.uri http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/9894
dc.description.abstract Background: There is still limited knowledge regarding the role of impaired brain glucose metabolism in the generation of aggression during diabetes. Additionally, there are rapidly replicating piece of evidence suggesting that topiramate may exert significant mood stabilizing effect. In this respect, we aimed to evaluate the neurometabolic correlates of the therapeutic effect of topiramate in a patient with diabetes and Intermittent explosive disorder (IED). Methods: We measured regional cerebral glucose metabolism using 2-[18F]-fluoro-2-deoxy-D-glucose and positron emission tomography (FDG-PET) in a diabetic patient with aggressive outbursts before and after treatment with topiramate. In order to reveal a defined information underlying the improvement of the aggressive symptoms we also combined the PET with Modified Overt Aggression Scale. Results: We have found that topiramate leads to the improvement in Modified Overt Aggression Scale that was well correlated with the increase in cortical brain metabolism. Discussion: The therapeutic role of topiramate may not only suggest secondary deficits due to diminished functions of the cortical part of emotional circuits but also indicate that diabetic individuals may be vulnerable to lower cerebral glucose metabolism in cortical regions. Further clinical trials that include well-conducted randomized controlled trials and cohort studies by using other methods (i.e., magnetic resonance spectroscopy and quantitative EEG analysis) are necessary to confirm our preliminary findings. © 2016 Bentham Science Publishers.
dc.language.iso English
dc.publisher Bentham Science Publishers B.V.
dc.relation.isversionof 10.2174/1871524916666160301102055
dc.rights info:eu-repo/semantics/closedAccess
dc.subject 2-[18F]-fluoro-2-deoxy-D-glucose and positron emission tomography
dc.subject Intermittent explosive disorder
dc.subject Topiramate
dc.subject fluorodeoxyglucose f 18
dc.subject topiramate
dc.subject fructose
dc.subject adult
dc.subject aggression
dc.subject Article
dc.subject behavior disorder
dc.subject brain metabolism
dc.subject controlled study
dc.subject diabetes mellitus
dc.subject glucose blood level
dc.subject glucose metabolism
dc.subject glucose transport
dc.subject human
dc.subject nuclear magnetic resonance imaging
dc.subject positron emission tomography
dc.subject analogs and derivatives
dc.subject animal
dc.subject blood
dc.subject brain
dc.subject case report
dc.subject diagnostic imaging
dc.subject drug effects
dc.subject male
dc.subject metabolism
dc.subject physiology
dc.subject procedures
dc.subject Adult
dc.subject Aggression
dc.subject Animals
dc.subject Brain
dc.subject Diabetes Mellitus
dc.subject Fructose
dc.subject Humans
dc.subject Male
dc.subject Positron-Emission Tomography
dc.title Topiramate: A novel therapeutic candidate for diabetes and aggression? positron emission tomography (PET) findings
dc.type Article
dc.relation.journal Central Nervous System Agents in Medicinal Chemistry
dc.identifier.volume 16
dc.identifier.issue 3
dc.identifier.startpage 227
dc.identifier.endpage 230
dc.relation.publicationCategory Uluslararası Hakemli Dergi
dc.identifier.index Scopus


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record